Cargando…
Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
OBJECTIVE: This study aimed to evaluate safety (infusion‐related reactions [IRRs]) and patient satisfaction (patient‐reported outcomes [PROs]) for at‐home ocrelizumab administration for patients with multiple sclerosis (MS). METHODS: This open‐label study included adult patients with an MS diagnosis...
Autores principales: | Barrera, Britney, Simpson, Haley, Engebretson, Eric, Sillau, Stefan, Valdez, Brooke, Parra‐González, José, Winger, Ryan C., Epperson, Lou Anne, Banks, Ashley, Pierce, Kathryn, Spotts, Melanie, O'Gean, Katie, Alvarez, Enrique, Gross, Robert, Piquet, Amanda L., Schreiner, Teri, Corboy, John R., Pei, Jinglan, Vollmer, Timothy L., Nair, Kavita V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109340/ https://www.ncbi.nlm.nih.gov/pubmed/36811392 http://dx.doi.org/10.1002/acn3.51745 |
Ejemplares similares
-
Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions
por: Alvarez, Enrique, et al.
Publicado: (2022) -
Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017) -
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020) -
Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020) -
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)